BioNTech (BNTX) stock traded higher on Tuesday after Jefferies upgraded the COVID-19 vaccine maker to Buy, citing the ...

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...

BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...

In a report released today, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on BioNTech SE (BNTX – Research Report), ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

2 variant. Lastly, BioNTech and DualityBio were granted Fast Track designation by the FDA for their investigational drug, BNT324/DB-1311, for treating metastatic castration-resistant prostate cancer.

Lastly, BioNTech and DualityBio were granted Fast Track designation by the FDA for their investigational drug, BNT324/DB-1311, for treating metastatic castration-resistant prostate cancer.

BioNTech stock has climbed 25% over four days as the German biotech rides a round of cancer treatment success from Summit ...

A new mRNA cancer vaccine developed by Moderna has shown promising early results in clinical trials. The vaccine, mRNA-4359, ...

The efficacy of rucaparib plus nivolumab was compared with rucaparib monotherapy as maintenance treatment for ovarian cancer.

Results for Pfizer’s ponsegromab looked promising, while BioNTech and Instil Bio capitalized on momentum surrounding a kind of bispecific antibody.